This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.

Non-invasive, personalized diagnostics of coronary artery disease

Cardiolens FFR-CT Pro® allows for a detailed anatomical and functional evaluation of coronary arteries.

Cardiolens FFR-CT Pro® is an innovative non-invasive diagnostic tool for examining coronary artery disease severity

The FFR-CT-based technology developed by Hemolens allows for a detailed anatomical and functional evaluation of coronary arteries using computational fluid dynamic principles.

Cardiolens FFR-CT Pro® analyzes data from two non-invasive diagnostic methods:

  • Coronary computed tomography angiography (CCTA)
  • Continuous non-invasive blood pressure (CNBP) monitoring

Expected benefits of Cardiolens FFR-CT Pro® Test

Possibility to use the method also in patients with contraindication to coronary angiography

Reduced hospitalizations and related costs

Fast and safe diagnostic method

Reduced risk and improved patient comfort

Non-invasive tool to obtain quantitative functional results of stenosis severity

Improved planning of invasive procedures based on functional FFR-CT data

Reduced number of unnecessary invasive catheterizations and coronary angiographies

What are the steps of the Cardiolens FFR-CT Pro® diagnostic test?


  • Log in to the Cardiolens FFR-CT Pro® platform
  • Enter patient history
  • Upload CT scans (CCTA)
  • Upload the CNBP signal


  • Generate a 3D reconstruction of the patient’s coronary artery network
  • Produce simulations of blood flow in the 3D coronary model on the basis of the CT images and CNBP measurements


  • Multi-point interactive measurements of virtual FFR of main arteries. 

Our pipeline

Cardiology & Cardio-radiology

A technology for healthcare providers to accurately diagnose patients with suspected ischemic heart disease.


Assessment of cerebral blood flow and brain perfusion as a significant diagnostic parameter in the diagnosis and treatment of stroke and brain aneurysms (in development).


Evaluation of hepatic, renal and cerebral blood flow and angiogenesis levels as a tool in planning optimal radio- and chemotherapy (in development).


Evaluation of pulmonary blood flow as an important diagnostic factor in the prevention and diagnostics of lung diseases (in development).


Assessment of blood flow in large vessels such as the aorta or femoral artery is an important prognostic of thrombotic lesions and a useful tool in planning the surgical treatment of embolisms (in development).